secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001437749-22-027267
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AcelRx reports Q3 net loss of $6.9M, DSUVIA sales up 217% YoY to $0.5M
----------------------------------------------------------------------

- DSUVIA net sales $0.5M in Q3 2022, up 217% vs Q3 2021; units sold 1,032 vs 371.
- Net loss $6.9M ($0.94 per share) vs $8.4M ($1.40) in Q3 2021; cash $20.9M.
- Combined R&D and SG&A expenses fell to $6.6M from $10.1M on cost reductions.
- Niyad development batch produced; potential EUA submission targeted for H1 2023.
- Ephedrine pre-filled syringe NDA submission expected by year-end; DSUVIA strategic partner by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774922027267/0001437749-22-027267-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774922027267/acrx20221111_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-027267

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer